首页> 外文期刊>Bioengineering & Translational Medicine >PRADA Portable Reusable Accurate Diagnostics with nanostar Antennas for multiplexed biomarker screening
【24h】

PRADA Portable Reusable Accurate Diagnostics with nanostar Antennas for multiplexed biomarker screening

机译:Prada便携式可重复使用的准确准确诊断,用于多路复用生物标志物筛选

获取原文
       

摘要

Precise monitoring of specific biomarkers in biological fluids with accurate biodiagnostic sensors is critical for early diagnosis of diseases and subsequent treatment planning. In this work, we demonstrated an innovative biodiagnostic sensor, portable reusable accurate diagnostics with nanostar antennas (PRADA), for multiplexed biomarker detection in small volumes (~50 μl) enabled in a microfluidic platform. Here, PRADA simultaneously detected two biomarkers of myocardial infarction, cardiac troponin I (cTnI), which is well accepted for cardiac disorders, and neuropeptide Y (NPY), which controls cardiac sympathetic drive. In PRADA immunoassay, magnetic beads captured the biomarkers in human serum samples, and gold nanostars (GNSs) “antennas” labeled with peptide biorecognition elements and Raman tags detected the biomarkers via surface‐enhanced Raman spectroscopy (SERS). The peptide‐conjugated GNS‐SERS barcodes were leveraged to achieve high sensitivity, with a limit of detection (LOD) of 0.0055 ng/ml of cTnI, and a LOD of 0.12 ng/ml of NPY comparable with commercially available test kits. The innovation of PRADA was also in the regeneration and reuse of the same sensor chip for ~14 cycles. We validated PRADA by testing cTnI in 11 de‐identified cardiac patient samples of various demographics within a 95% confidence interval and high precision profile. We envision low‐cost PRADA will have tremendous translational impact and be amenable to resource‐limited settings for accurate treatment planning in patients.
机译:精确地监测生物液体中的特定生物标志物,具有精确的生物血管血管传感器对于早期诊断和随后的治疗计划至关重要。在这项工作中,我们展示了一种创新的生物仿新性传感器,便携式可重复使用的可再现精确诊断与NanoStar天线(PRADA),用于在微流体平台中启用的小体积(〜50μL)中的多路复用生物标志物检测。这里,普拉达同时检测到两种心肌梗死的生物标志物,心肌肌钙蛋白I(CTNI),这对于心脏病,而神经肽Y(npy),其控制心脏紊乱。在PRADA免疫测定中,磁珠捕获了人血清样品中的生物标志物,并通过表面增强的拉曼光谱(SERS)检测了用肽生物释认元件和拉曼标签标记的金纳盘(GNSS)“天线”。利用肽 - 缀合的GNS-SERS条形码以实现高灵敏度,其检测限为0.0055ng / ml CTNI,以及0.12ng / ml与市售测试试剂盒相当的床位。普拉达的创新也在再生和再利用相同的传感器芯片〜14个循环。通过在95%置信区间和高精度型材的各种人口统计学的11个去识别的心脏患者样本中测试CTNI,通过测试CTNI验证了PRADA。我们设想低成本的PRADA将具有巨大的翻译影响,并适用于患者准确治疗计划的资源限制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号